TriSalus Life Sciences, Inc. (TLSI) Stock Analysis and Metrics

TriSalus Life Sciences

NASDAQ: TLSI

$4.22 ▼ -0.05 (-1.17%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap220.07 Mn

P/E-3.76

P/S4.90

Div. Yield0.00

Total Debt (Qtr)33.08 Mn

Revenue Growth (1y) (Qtr)-2.92

Add ratio to table…

About

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that seeks to transform treatment for patients with solid tumors by integrating its proprietary pressure-enabled drug delivery (PEDD) platform with standard-of-care therapies and its investigational immunotherapeutic nelitolimod, a class C Toll‑like receptor 9 agonist. The company’s PEDD technology addresses high intratumoral pressure and off‑target delivery, aiming to improve drug penetration and therapeutic efficacy in liver, pancreatic and other solid tumors. TriSalus markets the FDA‑cleared TriNav Infusion System for embolization procedures and continues to develop additional devices such as the pancreatic retrograde venous infusion (PRVI) system and the nelitolimod drug candidate for future combination therapies.

TriSalus generates revenue primarily from the sale of its FDA‑cleared TriNav Infusion System, which utilizes PEDD technology to enhance the delivery of therapeutic agents during transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) procedures. In 2025, TriNav sales amounted to $45.2 million, reflecting a year‑over‑year increase of 53.4%. The company also derives revenue from related disposable accessories and from the expansion of its PEDD‑based product line, including the TriNav FLX and TriNav XP variants, which address diverse anatomical challenges and broaden the addressable market for embolization therapies. While the pancreatic retrograde venous infusion (PRVI) device and the nelitolimod immunotherapeutic remain investigational and have not yet contributed to sales, they represent future growth opportunities.

TriSalus competes in the embolization device market against established products such as standard microcatheters, Embolix’s Sniper, and Merit Medical's Swift NINJA. Its competitive advantage lies in the proprietary PEDD mechanism, which actively modulates arterial pressure and flow to improve tumor‑to‑normal liver ratios and reduce non‑target embolization, a benefit demonstrated in multiple clinical studies and real‑world evidence analyses. The company’s intellectual property portfolio includes over 80 granted patents and pending applications covering the TriNav device, the PEDD method, and related technologies, providing a barrier to entry. Furthermore, TriSalus combines its device platform with the investigational nelitolimod agent, creating a potential combination therapy that could differentiate it from pure device competitors and open additional oncology indications.

TriSalus sells its products to hospitals and ambulatory surgery centers throughout the United States, focusing on institutions that perform high volumes of transarterial embolization procedures. The primary users of its technology are interventional radiologists who deploy the TriNav system during TARE and TACE, while medical oncologists, nursing staff, and hospital value‑analysis committees influence purchasing and adoption decisions. The company also engages with academic medical centers and research institutions to generate clinical data and support investigator‑initiated trials, further expanding its network of potential customers.

Investment Thesis

▲ Bull case

TriSalus is positioned to capture significant growth from its expanded commercial organization and real-world evidence validating PEDD's clinical and economic benefits, which the market may be underestimating as a near-term catalyst for adoption. The deliberate expansion of the sales force, including the addition of experienced leadership like Chris Sowd and a doubled organizational footprint, is designed to scale beyond current limitations and drive sustained revenue growth through Q3 and Q4 FY26 as reps ramp to productivity. This structural build-out, not a temporary setback, lays the foundation for multiyear growth by enabling deeper physician engagement across liver embolization and high-potential new applications like uterine artery embolization (UAE), thyroid artery embolization (TAE), and genicular artery embolization (GAE), which collectively represent a $2.5 billion addressable market. The landmark real-world evidence study demonstrating $7.7 thousand per patient in cost avoidance, reduced 30-day readmissions by over half in TACE patients, and preserved immune function through significantly lower lymphopenia rates provides compelling, peer-reviewed validation that resonates with both physicians and payers. This data is not merely supportive but transformative, as it directly addresses key barriers to adoption—proving PEDD enhances immunotherapy eligibility and reduces downstream costs—making it a powerful tool for commercial teams to accelerate institutional uptake. Furthermore, the pipeline of upcoming clinical readouts, including prospective trials at Stanford and MD Anderson and completed studies at Massachusetts General Hospital, is poised to deliver additional catalysts in the second half of FY26 that could drive adoption beyond current expectations, particularly in academic centers where head-to-head data influences guidelines. The market may be overlooking how this evidence base, combined with the scaled commercial infrastructure, creates a self-reinforcing cycle: stronger data drives adoption, which generates more real-world evidence, further validating PEDD’s value and expanding its utility across indications. With TriNav Advance clearance expected in the second half of FY26, TriSalus will gain access to distal vessels via microcatheters, unlocking an incremental market opportunity in super-selective procedures that physicians already prefer, thereby expanding the addressable patient pool without requiring changes to existing clinical workflows. This positions the company to not only meet its revised $54 million to $57 million FY26 revenue guidance but to exceed it as the commercial ramp accelerates and new applications gain traction, turning near-term investment into long-term, compounding growth.

TriSalus is positioned to capture significant growth from its expanded commercial organization and real-world evidence validating PEDD's clinical and economic benefits, which the market may be underestimating as a near-term catalyst for adoption. The deliberate expansion of the sales force, including the addition of experienced leadership like Chris Sowd and a doubled organizational footprint, is designed to scale beyond current limitations and drive sustained revenue growth through Q3 and Q4 FY26 as reps ramp to productivity. This structural build-out, not a temporary setback, lays the foundation for multiyear growth by enabling deeper physician engagement across liver embolization and high-potential new applications like uterine artery embolization (UAE), thyroid artery embolization (TAE), and genicular artery embolization (GAE), which collectively represent a $2.5 billion addressable market. The landmark real-world evidence study demonstrating $7.7 thousand per patient in cost avoidance, reduced 30-day readmissions by over half in TACE patients, and preserved immune function through significantly lower lymphopenia rates provides compelling, peer-reviewed validation that resonates with both physicians and payers. This data is not merely supportive but transformative, as it directly addresses key barriers to adoption—proving PEDD enhances immunotherapy eligibility and reduces downstream costs—making it a powerful tool for commercial teams to accelerate institutional uptake. Furthermore, the pipeline of upcoming clinical readouts, including prospective trials at Stanford and MD Anderson and completed studies at Massachusetts General Hospital, is poised to deliver additional catalysts in the second half of FY26 that could drive adoption beyond current expectations, particularly in academic centers where head-to-head data influences guidelines. The market may be overlooking how this evidence base, combined with the scaled commercial infrastructure, creates a self-reinforcing cycle: stronger data drives adoption, which generates more real-world evidence, further validating PEDD’s value and expanding its utility across indications. With TriNav Advance clearance expected in the second half of FY26, TriSalus will gain access to distal vessels via microcatheters, unlocking an incremental market opportunity in super-selective procedures that physicians already prefer, thereby expanding the addressable patient pool without requiring changes to existing clinical workflows. This positions the company to not only meet its revised $54 million to $57 million FY26 revenue guidance but to exceed it as the commercial ramp accelerates and new applications gain traction, turning near-term investment into long-term, compounding growth.

▼ Bear case

TriSalus faces substantial execution risks and market challenges that the market may be ignoring, particularly regarding the sustainability of its growth trajectory amid a costly commercial expansion and uncertain adoption timelines for new applications. The deliberate disruption of 40% of sales territories during Q1 FY26, involving simultaneous changes to rep-to-physician and rep-to-manager relationships, caused a measurable revenue shortfall versus the prior year ($8.9 million vs. $9.2 million), and while management frames this as a necessary investment, the pace of rep productivity recovery remains unproven and contingent on successful onboarding and relationship rebuilding—factors that could delay revenue ramp beyond current expectations, especially if the anticipated 6- to 9-month timeline proves optimistic given the complexity of selling into interventional radiology and oncology workflows. Despite the impressive real-world evidence showing cost avoidance and clinical benefits, the company has not disclosed specific adoption rates or contractual commitments from health systems post-publication, raising concerns that the data, while scientifically robust, may not translate quickly into revenue due to entrenched clinical practices, reimbursement uncertainty, or budget constraints at hospitals, particularly in community settings where PEDD’s value proposition requires overcoming inertia in established embolization techniques. The delayed FDA clearance for TriNav Advance, now running five months past the MDUFA goal, removes a key near-term growth driver from the second half of FY26 guidance, and while management remains confident, the inherent unpredictability of regulatory timing introduces downside risk to revenue projections, especially since the device is positioned to unlock access to small distal vessels—a critical advantage for super-selective procedures that could otherwise limit PEDD’s applicability in complex cases. Furthermore, the expansion into new applications like UAE, TAE, and GAE, while representing a $2.5 billion market, remains largely in early-stage clinical validation or pilot phases, with no clear timeline for pivotal trials, reimbursement pathways, or commercial scalability; investing in these areas diverts resources from the core liver embolization business without guaranteed near-term returns, and the company’s reliance on investigator-initiated trials and registries (e.g., PROTECT) for evidence generation may delay definitive data needed for broad adoption. Financially, TriSalus continues to operate with significant net losses ($8.4 million in Q1 FY26) and negative adjusted EBITDA ($5.8 million), and while its $56.6 million cash position provides a runway, the continued investment in sales force expansion, clinical studies, and regulatory efforts without a clear path to profitability in the near term raises questions about capital efficiency and the ability to sustain growth without additional dilutive financing, especially if revenue acceleration lags behind expense growth—a scenario that could undermine investor confidence despite the long-term narrative.

TriSalus faces substantial execution risks and market challenges that the market may be ignoring, particularly regarding the sustainability of its growth trajectory amid a costly commercial expansion and uncertain adoption timelines for new applications. The deliberate disruption of 40% of sales territories during Q1 FY26, involving simultaneous changes to rep-to-physician and rep-to-manager relationships, caused a measurable revenue shortfall versus the prior year ($8.9 million vs. $9.2 million), and while management frames this as a necessary investment, the pace of rep productivity recovery remains unproven and contingent on successful onboarding and relationship rebuilding—factors that could delay revenue ramp beyond current expectations, especially if the anticipated 6- to 9-month timeline proves optimistic given the complexity of selling into interventional radiology and oncology workflows. Despite the impressive real-world evidence showing cost avoidance and clinical benefits, the company has not disclosed specific adoption rates or contractual commitments from health systems post-publication, raising concerns that the data, while scientifically robust, may not translate quickly into revenue due to entrenched clinical practices, reimbursement uncertainty, or budget constraints at hospitals, particularly in community settings where PEDD’s value proposition requires overcoming inertia in established embolization techniques. The delayed FDA clearance for TriNav Advance, now running five months past the MDUFA goal, removes a key near-term growth driver from the second half of FY26 guidance, and while management remains confident, the inherent unpredictability of regulatory timing introduces downside risk to revenue projections, especially since the device is positioned to unlock access to small distal vessels—a critical advantage for super-selective procedures that could otherwise limit PEDD’s applicability in complex cases. Furthermore, the expansion into new applications like UAE, TAE, and GAE, while representing a $2.5 billion market, remains largely in early-stage clinical validation or pilot phases, with no clear timeline for pivotal trials, reimbursement pathways, or commercial scalability; investing in these areas diverts resources from the core liver embolization business without guaranteed near-term returns, and the company’s reliance on investigator-initiated trials and registries (e.g., PROTECT) for evidence generation may delay definitive data needed for broad adoption. Financially, TriSalus continues to operate with significant net losses ($8.4 million in Q1 FY26) and negative adjusted EBITDA ($5.8 million), and while its $56.6 million cash position provides a runway, the continued investment in sales force expansion, clinical studies, and regulatory efforts without a clear path to profitability in the near term raises questions about capital efficiency and the ability to sustain growth without additional dilutive financing, especially if revenue acceleration lags behind expense growth—a scenario that could undermine investor confidence despite the long-term narrative.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password